Eczema Awareness Monthly – An American Academy of Dermatology Official Licensee
0
  • Eczema
  • Articles
  • Expert Panel
  • Guidelines
  • Studies
  • Systematic Reviews
  • Patient Resources
Eczema Awareness Monthly - An American Academy of Dermatology Official Licensee
0
Eczema Awareness Monthly - An American Academy of Dermatology Official Licensee
  • Eczema
  • Articles
  • Expert Panel
  • Guidelines
  • Studies
  • Systematic Reviews
  • Patient Resources
Advertisement
EczemaStudies

The role of thymus and activation-regulated chemokine as a marker of severity of atopic dermatitis

Awareness Monthly
Posted by Awareness Monthly

The aspects of serum thymus and activation-regulated chemokine (TARC) was studied to assess severity and QoL in patients with atopic dermatitis.

Learn more at the Journal of the American Academy of Dermatology.

Share on
Share on Facebook Share on Twitter Share on Pinterest Share on Email
Awareness Monthly
Previous Article Tapinarof as an important advance in topical medicine development for AD
Next Article Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis
Advertisement

 

Advertisement

 

You Might Also Enjoy

ArticlesEczema

First Topical JAK Inhibitor for Atopic Dermatitis Receives FDA Approval

ArticlesEczema

Pediatric Atopic Dermatitis: Topical Calcineurin Inhibitors

ArticlesEczema

Atopic Dermatitis and COVID-19 Infection Risk

ArticlesEczema

Biologic for Atopic Dermatitis FDA Approved

Load More
Eczema Awareness Monthly - An American Academy of Dermatology Official Licensee

© 2020-2023 Powered by eHealthcare Solutions | Privacy Policy

×